BSE - Delayed Quote INR
Sudarshan Pharma Industries Limited (SUDARSHAN.BO)
26.66
-0.54
(-1.99%)
At close: May 2 at 11:15:00 AM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
4,635,416
4,635,416
4,613,319
3,570,946
1,933,503
Cost of Revenue
4,224,796
4,224,796
4,309,470
3,379,040
1,792,971
Gross Profit
410,620
410,620
303,849
191,906
140,532
Operating Expense
194,942
194,942
166,034
89,862
76,309
Operating Income
215,678
215,678
137,815
102,044
64,223
Net Non Operating Interest Income Expense
-89,445
-89,445
-54,023
-32,099
-32,000
Pretax Income
152,284
152,284
94,962
71,906
35,746
Tax Provision
37,732
37,732
24,595
18,870
9,034
Net Income Common Stockholders
114,553
114,553
70,367
53,036
26,712
Diluted NI Available to Com Stockholders
114,553
114,553
70,367
53,036
26,712
Basic EPS
4.76
4.76
2.92
2.20
1.11
Diluted EPS
4.76
4.76
2.92
2.20
1.11
Basic Average Shares
24,065.76
24,065.76
24,098.29
24,065.89
24,065.89
Diluted Average Shares
24,065.76
24,065.76
24,098.29
24,065.89
24,065.89
Rent Expense Supplemental
--
--
--
5,816
4,362
Total Expenses
4,419,738
4,419,738
4,475,504
3,468,902
1,869,280
Net Income from Continuing & Discontinued Operation
114,553
114,553
70,367
53,036
26,712
Normalized Income
114,553
114,553
70,367
53,767.67
26,712
Interest Income
--
--
--
1,692
253
Interest Expense
89,445
89,445
54,023
28,708
28,559
Net Interest Income
-89,445
-89,445
-54,023
-32,099
-32,000
EBIT
241,729
241,729
148,985
100,614
64,305
EBITDA
254,173
254,173
158,056
109,273
71,728
Reconciled Cost of Revenue
4,224,796
4,224,796
4,309,470
3,379,040
1,792,971
Reconciled Depreciation
12,444
12,444
9,071
8,659
7,423
Net Income from Continuing Operation Net Minority Interest
114,553
114,553
70,367
53,036
26,712
Total Unusual Items Excluding Goodwill
--
--
--
-992
--
Total Unusual Items
--
--
--
-992
--
Normalized EBITDA
254,173
254,173
158,056
110,265
71,728
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
--
--
--
-260.33
--
3/31/2021 - 3/20/2023
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade